Ascelia Pharma - Presentation of Q3 2023

Meet and ask questions CEO Magnus Corfitzen from Ascelia Pharma on 9 November at 2.30PM CET.

The topic for this event is the Q3 report and major events during the quarter. It’s been a very busy quarter for Ascelia Pharma with major news flow on the Sparkle study.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 3.11 PM 18 October 2023.